We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multip... Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Show more
Updated Phase 1 data demonstrate a 12-month overall survival (OS) of 71% and 18-month OS of 62% Company plans to discuss encouraging Phase 2 interim results with the FDA Company plans to submit...
Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse...
FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1st and 2nd line standard of care treatments Data from Phase 1 of BOT/BAL...
Preclinical findings demonstrate superior pharmacological activity, offering a differentiated mechanism-of-action to enhance anti-tumor immunity in advanced solid cancers Agenus Inc. (“Agenus”...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board...
Conference Call on Thursday, March 14, 2024 at 8:30 a.m. ET Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.12 | -37.0106761566 | 8.43 | 9.22 | 4.775 | 1475126 | 6.20321591 | CS |
4 | -6.102 | -53.4700315457 | 11.412 | 11.83 | 4.775 | 7282115 | 9.89725485 | CS |
12 | -7.062 | -57.0805043647 | 12.372 | 18.98 | 4.775 | 10392452 | 12.72737241 | CS |
26 | -15.29 | -74.2233009709 | 20.6 | 21.2 | 4.775 | 10425443 | 13.88344326 | CS |
52 | -28.69 | -84.3823529412 | 34 | 42.6 | 4.775 | 7514675 | 19.07212708 | CS |
156 | -47.29 | -89.9049429658 | 52.6 | 135.8 | 4.775 | 5517061 | 42.54607516 | CS |
260 | -46.09 | -89.6692607004 | 51.4 | 135.8 | 4.775 | 4157793 | 48.25279495 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions